Polynovo Limited (CALZF)
OTHER OTC:CALZF
CALZF Stock Chart & Stats
$0.73
-$0.78(-42.86%)
At close: 4:00 PM EST
$0.73
-$0.78(-42.86%)
Day’s Range― - ―
52-Week Range$0.55 - $1.03
Previous CloseN/A
Volume1.00K
Average Volume (3M)1.06K
Market Cap
$546.50M
Enterprise Value$845.35M
Total Cash (Recent Filing)$29.26M
Total Debt (Recent Filing)$31.74M
Price to Earnings (P/E)77.3
Beta1.91
Next Earnings
Aug 21, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding690,843,000
10 Day Avg. Volume2,300
30 Day Avg. Volume1,056
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)9.95
Price to Sales (P/S)6.51
P/FCF Ratio-76.87
Enterprise Value/Market Cap1.55
Enterprise Value/Revenue6.13
Enterprise Value/Gross Profit18.97
Enterprise Value/Ebitda118.71
Forecast
1Y Price Target
$1.12Price Target Upside53.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)<0.01
Revenue Forecast (FY)$109.18M
Bulls Say, Bears Say
Bulls Say
High Margins & Revenue GrowthExceptionally high gross margin (95.92%) alongside reported revenue growth signals durable unit economics and pricing power for NovoSorb products. Strong product-level margins support reinvestment, scalability, and insulation from modest cost pressures across multiple markets.
U.S. Commercial Scale & Account GrowthRapid U.S. expansion (double-digit sales growth and expanding installed base of 800+ hospital accounts) strengthens recurring, procedure-linked revenue. A growing account footprint and a >80‑rep commercial team deepen clinical adoption and improve long-term revenue predictability per market.
Manufacturing Scale & Regulatory ProgressA ~5x increase in production capacity materially raises the firm's ability to scale SKUs, lower per‑unit costs, and meet demand as adoption grows. Coupled with an advancing PMA pathway and robust clinical evidence, capacity supports durable commercialisation and faster market penetration.
Bears Say
Weak Cash ConversionMaterial disconnect between accounting profitability and cash generation (low OCF-to-net-income and negative FCF growth) constrains internal funding for commercial expansion and capex. Persistent weak cash conversion raises reliance on external financing and risks on investing flexibility.
Outpatient Reimbursement UncertaintyStructural uncertainty around CMS outpatient reimbursement and the likely need for an RCT delays broad office-based adoption. Until formal coverage is secured, outpatient revenue remains upside and market access timing could materially limit addressable market growth in the medium term.
Lumpy Burn Market & No Formal GuidanceReliance on episodic large burn cases makes demand lumpy and forecasting difficult. Management's refusal to give formal guidance reflects this structural volatility, complicating capacity planning, inventory management and investor visibility for multi‑period resource allocation.
Polynovo News
CALZF FAQ
What was Polynovo Limited’s price range in the past 12 months?
Polynovo Limited lowest stock price was $0.55 and its highest was $1.03 in the past 12 months.
What is Polynovo Limited’s market cap?
Polynovo Limited’s market cap is $546.50M.
When is Polynovo Limited’s upcoming earnings report date?
Polynovo Limited’s upcoming earnings report date is Aug 21, 2026 which is in 78 days.
How were Polynovo Limited’s earnings last quarter?
Polynovo Limited released its earnings results on Feb 20, 2026. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.004 by -$0.004.
Is Polynovo Limited overvalued?
According to Wall Street analysts Polynovo Limited’s price is currently Undervalued.
Does Polynovo Limited pay dividends?
Polynovo Limited does not currently pay dividends.
What is Polynovo Limited’s EPS estimate?
Polynovo Limited’s EPS estimate is <0.01.
How many shares outstanding does Polynovo Limited have?
Polynovo Limited has 690,843,000 shares outstanding.
What happened to Polynovo Limited’s price movement after its last earnings report?
Polynovo Limited reported an EPS of $0 in its last earnings report, missing expectations of $0.004. Following the earnings report the stock price went down -3.116%.
Which hedge fund is a major shareholder of Polynovo Limited?
Currently, no hedge funds are holding shares in CALZF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Polynovo Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.12 (53.40% Upside)
$1.12 (53.40% Upside)
Blogger Sentiment
Bullish
CALZF Sentiment 97%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $101.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.28%
12-Months-Change
Fundamentals
Return on Equity
11.87%
Trailing 12-Months
Asset Growth
17.90%
Trailing 12-Months
Company Description
Polynovo Limited
PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
CALZF Company Deck
CALZF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive operational and commercial picture: double‑digit revenue growth across major regions (group +26%, U.S. +25.3%, RoW +28.3%), rapid MTX adoption (~+193%), improved cash flow (+$9.0M) and a strong clinical evidence base (348 studies). Key strategic catalysts (PMA submission, SynPath outpatient pathway, expanded manufacturing capacity, recruitment of a Chief Scientific Officer) provide clear upside. Short‑term headwinds include a timing‑related manufacturing variance (~$3.6–3.7M) from planned slowdowns, an R&D lab fire asset write‑off (insured), FX translation losses, and reimbursement/regulatory uncertainty for outpatient CMS coverage which may require an RCT. Management frames several negatives as one‑offs or timing issues and expects margin and free cash flow improvement in H2. Overall, highlights materially outweigh the lowlights.View all CALZF earnings summariesCALZF Stock 12 Month Forecast
Average Price Target
$1.12
▲(53.40% Upside)
Technical Analysis
Nova Eye Medical
―
Cochlear
―
Micro-X Ltd.
―
Aroa Biosurgery Ltd
―
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
―
Ownership Overview
3.36% Insiders
2.74% Mutual Funds
― Other Institutional Investors
91.22% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---